Recursion Pharmaceuticals, Inc. (RXRX) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Recursion Pharmaceuticals, Inc. (RXRX:NASDAQ), powered by AI.
- Current Price
- $3.15
- P/E Ratio
- -2.2
- Market Cap
- 1.4B
- Sector
- Healthcare
What is the Recursion Pharmaceuticals, Inc. stock price forecast?
Recursion Pharmaceuticals, Inc. is currently trading at $3.15. View real-time AI analysis on Alpha Lenz.
What is Recursion Pharmaceuticals, Inc. insider trading activity?
View the latest insider trading data for Recursion Pharmaceuticals, Inc. on Alpha Lenz.
What is Recursion Pharmaceuticals, Inc.'s P/E ratio?
Recursion Pharmaceuticals, Inc.'s P/E ratio is -2.2.
Recursion Pharmaceuticals, Inc.
NASDAQ · RXRX“Recursion Pharmaceuticals, Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -59.5%. 3Y revenue CAGR of 23.2% highlights clear growth momentum.”
Ask for details →Company Overview
Recursion Pharmaceuticals Inc. is a biotechnology company focused on utilizing machine learning and artificial intelligence to accelerate drug discovery and development. By integrating cutting-edge computational methods with traditional laboratory techniques, Recursion aims to systematize and scale the identification of potential therapeutic compounds across various diseases. The company's proprietary Recursion Operating System is designed to handle vast amounts of biological and chemical data, generating insights that enhance the probability of finding effective treatments for complex disorders. Recursion's operations impact key sectors such as healthcare, pharmaceuticals, and biotechnology, emphasizing personalized medicine and innovative therapeutic solutions. Headquartered in Salt Lake City, Utah, Recursion stands out in the biotech market for its commitment to revolutionizing the drug discovery process, making it faster and more efficient through tech-driven approaches.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Recursion Pharmaceuticals, Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -59.5%. 3Y revenue CAGR of 23.2% highlights clear growth momentum.”
Ask for details →Frequently Asked Questions
Recursion Pharmaceuticals, Inc. (ticker: RXRX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 800 employees. Market cap is $1.4B.
The current price is $3.15 with a P/E ratio of -2.19x and P/B of 1.25x.
ROE is -59.54% and operating margin is -872.83%. Annual revenue is $74M.